Results 31 to 40 of about 1,112,598 (185)

P-ANCA vasculitic neuropathy with 12-year latency between onset of neuropathy and systemic symptoms

open access: yesBMC Neurology, 2002
Background The differential diagnosis of chronic progressive multifocal asymmetric neuropathies is challenging. Vasculitic neuropathies, multifocal forms of chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathies, and asymmetric ...
Greenberg Steven A
doaj   +1 more source

Different IVIG glycoforms affect in vitro inhibition of anti-ganglioside antibody-mediated complement deposition. [PDF]

open access: yesPLoS ONE, 2014
Intravenous immunoglobulin (IVIG) is the first line treatment for Guillain-Barré syndrome and multifocal motor neuropathy, which are caused by anti-ganglioside antibody-mediated complement-dependent cytotoxicity.
Makoto Sudo   +6 more
doaj   +1 more source

Long-term treatment with subcutaneous immunoglobulin in multifocal motor neuropathy

open access: yesScientific Reports, 2021
Multifocal motor neuropathy (MMN) is a rare disease with a prevalence of less than 1 per 100,000 people. Intravenous immunoglobulin (IVIG) therapy, performed for a long-term period, has been demonstrated able to improve the clinical picture of MMN ...
Luca Gentile   +6 more
doaj   +1 more source

Multifocal motor neuropathy

open access: yesCurrent Opinion in Neurology, 2018
Purpose of review Multifocal motor neuropathy (MMN) has specific clinical and electrophysiologic features but can be difficult to diagnose if cases are not typical. Intravenous immunoglobulin (IVIg) remains the core initial and long-term treatment.
Katie, Beadon   +2 more
openaire   +3 more sources

Multifocal motor neuropathy and visual pathway impairment: A case report

open access: yesClinical Neurophysiology Practice, 2021
Background: Multifocal motor neuropathy (MMN) occasionally presents with cranial nerve involvement. However, no MMN cases with visual pathway impairment demonstrated by visual evoked potential (VEP) have been reported.
Keisuke Kido   +5 more
doaj   +1 more source

Immunosuppressive treatment in multifocal motor neuropathy [PDF]

open access: yes, 1991
We report the results of immunosuppressive treatments of 13 patients with multifocal motor neuropathy and elevated titers of serum antibodies to the GM1 ganglioside. All patients failed to respond to oral prednisone.
Feldman, Eva L.   +3 more
core   +1 more source

Multifocal Motor Neuropathy Presenting as Pseudodystonia [PDF]

open access: yes, 2017
Multifocal motor neuropathy (MMN) is an immune-mediated neuropathy. Wasting and weakness typically dominate the clinical presentation. We describe  four cases presenting with prominent cramping resembling a primary movement disorder.
Yiannikas, C   +9 more
core   +1 more source

Multifocal acquired demyelinating sensory and motor neuropathy misdiagnosed as carpal tunnel syndrome: a case report

open access: yesJournal of International Medical Research, 2021
Multifocal acquired demyelinating sensory and motor neuropathy (MADSAM), a subtype of chronic inflammatory demyelinating polyneuropathy, is a non-compressive peripheral nerve disorder. Symptoms of MADSAM include asymmetrical weakness and sensory deficits
Soyoung Kwak   +3 more
doaj   +1 more source

IVIG blocks complement deposition mediated by anti-GM1 antibodies in multifocal motor neuropathy

open access: yes, 2010
The pathogenesis of multifocal motor neuropathy (MMN) has yet to be established. MMN patients often carry anti-GM1 IgM antibodies, suggesting an autoimmune process involving complement.
T. Nakajima   +11 more
core   +1 more source

Pathophysiology of conduction block in multifocal motor neuropathy

open access: yes, 2007
Multifocal motor neuropathy (MMN) is a rare disorder of the peripheral nervous system characterised by the presence of focal motor conduction blocks. Although the pathological basis of conduction block is believed to be focal demyelination, in multifocal
E. Nobile-Orazio   +4 more
core   +2 more sources

Home - About - Disclaimer - Privacy